UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 1.190

Sortiert nach

Hypophosphatemia attenuates improvements in vitality after intravenous iron treatment in patients with inflammatory bowel disease

Quality of life research, 2024-08, Vol.33 (8), p.2285-2294

2024

Volltextzugriff (PDF)

Intravenous iron treatments for iron deficiency anemia in inflammatory bowel disease: a budget impact analysis of iron isomaltoside 1000 (Monofer) in the UK

Expert opinion on drug delivery, 2017-12, Vol.14 (12), p.1439-1446

2017

Volltextzugriff (PDF)

Evaluating the cost-effectiveness of reduced mild hypoglycaemia in subjects with Type 1 diabetes treated with insulin detemir or NPH insulin in Denmark, Sweden, Finland and the Netherlands

Diabetic medicine, 2012-03, Vol.29 (3), p.303-312

2012

Volltextzugriff (PDF)

A cost-utility analysis of SIR-Spheres Y-90 resin microspheres versus best supportive care in the treatment of unresectable metastatic colorectal cancer refractory to chemotherapy in the UK

Journal of medical economics, 2020-12, Vol.23 (12), p.1588-1597

2020

Volltextzugriff (PDF)

A short-term cost-utility analysis of insulin degludec versus insulin glargine U100 in patients with type 1 or type 2 diabetes in Denmark

Journal of medical economics, 2017-03, Vol.20 (3), p.213-220

2017

Volltextzugriff (PDF)

Evaluating the economic implications of non-adherence and antibody-mediated rejection in renal transplant recipients: the role of once-daily tacrolimus in the UK

Journal of medical economics, 2015-12, Vol.18 (12), p.1050-1059

2015

Volltextzugriff (PDF)

A Cost-Utility Analysis of SQ ® Tree SLIT-Tablet versus Placebo in the Treatment of Birch Pollen Allergic Rhinitis from a Swedish Societal Perspective

ClinicoEconomics and outcomes research, 2023-01, Vol.15, p.69-86

2023

Volltextzugriff (PDF)

Evaluation of the cost-utility of insulin degludec vs insulin glargine in Sweden

Journal of medical economics, 2013-12, Vol.16 (12), p.1442-1452

2013

Volltextzugriff (PDF)

Is the current standard of care leading to cost-effective outcomes for patients with type 2 diabetes requiring insulin? A long-term health economic analysis for the UK

Diabetes research and clinical practice, 2015-07, Vol.109 (1), p.95-103

2015

Volltextzugriff (PDF)

A Cost-Utility Analysis of Prolonged-Release Tacrolimus Relative to Immediate-Release Tacrolimus and Ciclosporin In Liver Transplant Recipients In The Uk

Value in health, 2015-11, Vol.18 (7), p.A628-A629

2015

Volltextzugriff (PDF)

Evaluating The Cost-Effectiveness of Prolonged-Release Tacrolimus Relative to Immediate-Release Tacrolimus In Liver Transplant Patients Based on Data From Routine Clinical Practice

Value in health, 2015-11, Vol.18 (7), p.A626-A626

2015

Volltextzugriff (PDF)

Cost-Effectiveness of Rapid-Acting Analog Insulin for Type 1 Diabetes In The Uk Setting

Value in health, 2015-11, Vol.18 (7), p.A610-A610

2015

Volltextzugriff (PDF)

Verification and Validation of Health Economic Models for Diabetes

Value in health, 2015-11, Vol.18 (7), p.A702-A702

2015

Volltextzugriff (PDF)

Long-term cost-effectiveness of insulin detemir versus NPH insulin in type 2 diabetes in Sweden

Journal of medical economics, 2012-10, Vol.15 (5), p.977-986

2012

Volltextzugriff (PDF)

Laparoscopic adjustable gastric banding vs standard medical management in obese patients with type 2 diabetes: a budget impact analysis in the UK

Journal of medical economics, 2013-02, Vol.16 (2), p.249-259

2013

Volltextzugriff (PDF)

The cost effectiveness of rapid-acting insulin aspart compared with human insulin in type 2 diabetes patients: an analysis from the Japanese third-party payer perspective

Journal of medical economics, 2011, Vol.14 (1), p.36-46

2011

Volltextzugriff (PDF)

EE137 Evaluating the Effects of the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model Risk Factor Progression Equations on Cost-Utility Outcomes in Type 2 Diabetes: Analyses Using the Prime Diabetes Model

Value in health, 2022-12, Vol.25 (12), p.S79-S79

2022

Volltextzugriff (PDF)

EE662 Cost-Effectiveness of Iron Chelation Therapies for the Treatment of Transfusional Iron Overload in Β-Thalassaemia, Sickle Cell Disease, and Myelodysplastic Syndrome: A Literature Review

Value in health, 2022-12, Vol.25 (12), p.S187-S187

2022

Volltextzugriff (PDF)

MSR66 Implementation of Contrast-Based and Shared Parameter Models in Bugsnet, an R Package for Conducting Bayesian Network Meta-Analysis

Value in health, 2022-07, Vol.25 (7), p.S531

2022

Volltextzugriff (PDF)

PCR104 Improvements in Health Utility Scores after Administration of Ferric Derisomaltose Versus Ferric Carboxymaltose in Patients with Inflammatory Bowel Disease and Iron Deficiency Anemia

Value in health, 2022-07, Vol.25 (7), p.S560

2022

Volltextzugriff (PDF)

Modelling the impact of sublingual immunotherapy versus subcutaneous immunotherapy on patient travel time and CO2 emissions in Sweden

Scientific reports, 2024, Vol.14 (1), p.1575-1575, Article 1575

2024

Volltextzugriff (PDF)

EE68 A UK Cost-Utility Analysis of Ferric Carboxymaltose Versus Ferric Derisomaltose in Patients with Iron Deficiency Anemia and Inflammatory Bowel Disease: Incorporation of Fracture Data

Value in health, 2024-06, Vol.27 (6), p.S69-S70

2024

Volltextzugriff (PDF)

EE400 Comparing the Budget Impact of Selective Internal Radiation Therapy Using Y-90 Resin Microspheres Versus Drug Eluting Bead Transarterial Chemoembolization in Hepatocellular Carcinoma in England

Value in health, 2022-12, Vol.25 (12), p.S134-S134

2022

Volltextzugriff (PDF)

An Economic Analysis of Ferric Derisomaltose versus Ferric Carboxymaltose in the Treatment of Iron Deficiency Anemia in Patients with Inflammatory Bowel Disease in Norway, Sweden, and Finland

ClinicoEconomics and outcomes research, 2021-01, Vol.13, p.9-18

2021

Volltextzugriff (PDF)

EE395 A Cost-Utility Analysis of Ferric Derisomaltose Versus Ferric Carboxymaltose in Patients With Inflammatory Bowel Disease in the United Kingdom

Value in health, 2022-12, Vol.25 (12), p.S133-S133

2022

Volltextzugriff (PDF)

1 – 25 von 1.190

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.005)
Mit Volltextzugriff
(1.039)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

EZB Free E-Journals
(509)
MEDLINE
(498)
Journals@Ovid Full Text
(438)
Ingenta
(430)
Publisher website
(371)
Elsevier ScienceDirect Journals Complete
(227)
Wiley Online Library
(212)
IngentaConnect Journals
(173)
Wiley Online Library Full Collection 2018
(128)
Elsevier Journal Backfiles on ScienceDirect (DFG Nationallizenzen)
(120)
American Physical Society Journals
(83)
PROLA
(81)
Springer journals
(74)
Ebook Central Perpetual and DDA
(72)
eBooks on EBSCOhost
(71)
Wiley Online Library All Obooks
(63)
Oxford journals
(59)
JSTOR Complete Journals
(54)
SpringerLINK Contemporary (Konsortium Baden-Württemberg)
(51)
Nature
(39)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(8)

Menü

Weitere Dienste

Einstellungen

Hypophosphatemia attenuates improvements in vitality after intravenous iron treatment in patients with inflammatory bowel disease

Intravenous iron treatments for iron deficiency anemia in inflammatory bowel disease: a budget impact analysis of iron isomaltoside 1000 (Monofer) in the UK

Evaluating the cost-effectiveness of reduced mild hypoglycaemia in subjects with Type 1 diabetes treated with insulin detemir or NPH insulin in Denmark, Sweden, Finland and the Netherlands

A cost-utility analysis of SIR-Spheres Y-90 resin microspheres versus best supportive care in the treatment of unresectable metastatic colorectal cancer refractory to chemotherapy in the UK

A short-term cost-utility analysis of insulin degludec versus insulin glargine U100 in patients with type 1 or type 2 diabetes in Denmark

Evaluating the economic implications of non-adherence and antibody-mediated rejection in renal transplant recipients: the role of once-daily tacrolimus in the UK

A Cost-Utility Analysis of SQ ® Tree SLIT-Tablet versus Placebo in the Treatment of Birch Pollen Allergic Rhinitis from a Swedish Societal Perspective

Evaluation of the cost-utility of insulin degludec vs insulin glargine in Sweden

Is the current standard of care leading to cost-effective outcomes for patients with type 2 diabetes requiring insulin? A long-term health economic analysis for the UK

A Cost-Utility Analysis of Prolonged-Release Tacrolimus Relative to Immediate-Release Tacrolimus and Ciclosporin In Liver Transplant Recipients In The Uk

Evaluating The Cost-Effectiveness of Prolonged-Release Tacrolimus Relative to Immediate-Release Tacrolimus In Liver Transplant Patients Based on Data From Routine Clinical Practice

Cost-Effectiveness of Rapid-Acting Analog Insulin for Type 1 Diabetes In The Uk Setting

Verification and Validation of Health Economic Models for Diabetes

Long-term cost-effectiveness of insulin detemir versus NPH insulin in type 2 diabetes in Sweden

Laparoscopic adjustable gastric banding vs standard medical management in obese patients with type 2 diabetes: a budget impact analysis in the UK

The cost effectiveness of rapid-acting insulin aspart compared with human insulin in type 2 diabetes patients: an analysis from the Japanese third-party payer perspective

EE137 Evaluating the Effects of the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model Risk Factor Progression Equations on Cost-Utility Outcomes in Type 2 Diabetes: Analyses Using the Prime Diabetes Model

EE662 Cost-Effectiveness of Iron Chelation Therapies for the Treatment of Transfusional Iron Overload in Β-Thalassaemia, Sickle Cell Disease, and Myelodysplastic Syndrome: A Literature Review

MSR66 Implementation of Contrast-Based and Shared Parameter Models in Bugsnet, an R Package for Conducting Bayesian Network Meta-Analysis

PCR104 Improvements in Health Utility Scores after Administration of Ferric Derisomaltose Versus Ferric Carboxymaltose in Patients with Inflammatory Bowel Disease and Iron Deficiency Anemia

Modelling the impact of sublingual immunotherapy versus subcutaneous immunotherapy on patient travel time and CO2 emissions in Sweden

EE68 A UK Cost-Utility Analysis of Ferric Carboxymaltose Versus Ferric Derisomaltose in Patients with Iron Deficiency Anemia and Inflammatory Bowel Disease: Incorporation of Fracture Data

EE400 Comparing the Budget Impact of Selective Internal Radiation Therapy Using Y-90 Resin Microspheres Versus Drug Eluting Bead Transarterial Chemoembolization in Hepatocellular Carcinoma in England

An Economic Analysis of Ferric Derisomaltose versus Ferric Carboxymaltose in the Treatment of Iron Deficiency Anemia in Patients with Inflammatory Bowel Disease in Norway, Sweden, and Finland

EE395 A Cost-Utility Analysis of Ferric Derisomaltose Versus Ferric Carboxymaltose in Patients With Inflammatory Bowel Disease in the United Kingdom

Suchergebnisse filtern